Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

American Family Physician March 1, 2004	Osteoporosis The definition, signs, and who's at risk of getting osteoporosis.
American Family Physician March 1, 2001	What You Should Know About Osteoporosis What is osteoporosis?... Who gets osteoporosis?... What are the effects of osteoporosis?... How does my doctor know I have osteoporosis?... How is osteoporosis treated?... How is osteoporosis prevented?... etc.
American Family Physician March 15, 2001 Jeannette E. South-Paul	Osteoporosis: Part II. Nonpharmacologic and Pharmacologic Treatment Family physicians will frequently encounter patients with osteoporosis, a condition that is often asymptomatic until a fracture occurs...
Nurse Practitioner June 2009 Ivy M. Alexander	Pharmacotherapeutic management of osteoporosis and osteopenia The estimated number of individuals with osteoporosis and osteopenia, the precursor to osteoporosis, continues to increase.
American Journal of Nursing August 2011 Karen Roush	Prevention and Treatment of Osteoporosis in Postmenopausal Women: A Review This article provides an overview of osteoporosis, describes current recommendations for its prevention and treatment, and discusses nursing implications.
Science News August 28, 2004	Bone Biology A new Web site provides information to physicians and others about bone physiology and osteoporosis.
American Family Physician March 1, 2001 Jeannette E. South-Paul	Osteoporosis: Part I. Evaluation and Assessment Because osteoporosis is usually asymptomatic until a fracture occurs, family physicians must identify the appropriate timing and methods for screening those at risk...
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
American Family Physician April 1, 2003 Campion & Maricic	Osteoporosis in Men Osteoporosis in men is now recognized as an increasingly important public health issue. Increased awareness by physicians of risk factors for male osteoporosis -- and early diagnosis and treatment -- are needed to decrease the morbidity and mortality resulting from osteoporotic fractures.
BusinessWeek June 21, 2004 Carol Marie Cropper	Osteoporosis: Men Suffer, Too Bone loss is a bigger threat than prostate cancer for men.
Chemistry World January 24, 2008 Jonathan Edwards	Trio of Papers Cast Doubts on Osteoporosis Treatment Calcium isn't as effective or safe as previously thought, and millions of people may be taking unnecessary preventative treatments.
HHMI Bulletin May 2011 Dan Ferber	Revealing the Biological Complexity of Bones Bones are the body's framework and support, our strongest tissues. Unlike the scaffold of a building, however, bones are anything but inert. They pulse with life and their maintenance requires a surprisingly delicate balancing act.
Nutra Solutions July 23, 2007 Ginny Banks	A New Look at Bone Health Although vitamin D and calcium are the mainstay ingredients for osteoporosis prevention, studies show that vitamin K2, phosphorous, magnesium, prebiotics and soy can also play a role.
American Family Physician October 1, 2004 Thomas M. Zizic	Pharmacologic Prevention of Osteoporotic Fractures Of the drugs that have been approved for the prevention or treatment of osteoporosis, the bisphosphonates (risedronate and alendronate) are most effective in reducing the risk of vertebral and nonvertebral fractures.
Salon.com July 10, 2002 Trisha Posner	Death by hormones It's been more than 50 years since studies first sounded the alarm about hormone replacement therapy. Women, silenced by shame, have been guinea pigs of the pharmaceutical industry for too long.
The Motley Fool May 13, 2005 Karl Thiel	Boning Up on New Drugs Are new osteoporosis therapies compelling investments, or is the field too crowded?
American Family Physician April 15, 2004 Bazaldua & Bruder	STEPS Drug Update Teriparatide (Forteo) for Osteoporosis
Nurse Practitioner July 2011 Kass-Wolff & Fisher	Menopause and the Hormone Controversy: Clarification or Confusion? Hormone therapy in perimenopause and menopause remains a controversial and often confusing management strategy for healthcare providers. To assist in providing women quality healthcare, recently published new guidelines help provide direction for NPs.
American Journal of Nursing June 2011 Karen Roush	Menopausal Hormone Therapy: What We Know Now This article describes the findings and limitations of the major research thus far on hormone therapy.
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool September 20, 2007 Billy Fisher	More Options for Healthy Bones? Novartis and Wyeth might be able to offer alternative treatments for osteoporosis, but the companies have a tough road ahead in this market.
The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool October 7, 2004 Charly Travers	Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful.
The Motley Fool September 17, 2007 Brian Orelli	Preventing Cancer, No Bones About It For Eli Lilly, the only thing better than having a drug with more than $1 billion in annual sales is getting it approved to treat more patients. That's what just happened with their cancer drug, EVISTA. Investors, take note.
The Motley Fool December 10, 2010 Brian Orelli	Something Is Better Than Nothing, I Guess Novartis' Zometa fails a critical clinical trial.
American Family Physician December 15, 2005 Janelle Guirguis-Blake	Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women The case study and answers to the following questions on hormone therapy for the prevention of chronic conditions in postmenopausal women are based on the recommendations of the U.S. Preventive Services Task Force (USPSTF).
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
BusinessWeek August 13, 2009 Arlene Weintraub	Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics.
The Motley Fool September 2, 2009 Robert Steyer	Pharma's Next Home Run Drug Could Be 4 Singles Instead With mixed success in the women's health field, drugmakers try to turn a single compound into a treatment for several diseases and conditions.
Seasoned Cooking July 2005 Michael Fick	Dem Bones Unless we patients, our doctors, and the whole medical profession change our acts, our aging population, lazier lifestyles, and junk food diets will lead to half of Americans over the age of 50 having osteoporosis or being at high risk for it.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
Food Processing June 2011 Dave Fusaro	How Can Food Processors Help Consumers' Aching and Aging Bones? Beyond vitamin D and phosphate, new ingredients help support calcium.
Delicious Living April 2005 Anne Burnett	Kids need calcium and exercise Researchers suggest that because at least 90 percent of peak bone mass is accrued by the end of adolescence, it is important to optimize bone growth in younger years.
The Motley Fool February 26, 2010 Brian Orelli	Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market.
BusinessWeek July 3, 2006 Catherine Arnst	A Ton Of Prevention The pros and cons of two drugs that may halve your risk of breast cancer.
Pharmaceutical Executive October 1, 2008 Joanna Breitstein	The D-Mab Men Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug for the multi-billion dollar osteoporosis market
The Motley Fool July 8, 2009 Brian Orelli	Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park.
Chemistry World July 12, 2007 Victoria Gill	Older Women Should Not Use HRT A long-term clinical trial into hormone replacement therapy has confirmed that HRT should not be prescribed to older women many years past menopause.
The Motley Fool August 19, 2009 Brian Orelli	Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.
Food Processing June 2013 Mark Anthony	Boning Up on Nutrition: Food Manufacturers Take a Closer Look at Dietary Calcium With a $4 billion bone and joint health market, functional ingredient manufacturers look to dietary calcium and Vitamin D's capabilities to help restore cracks in bone health.
The Motley Fool August 14, 2009 Brian Orelli	Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
Health August 24, 2009 Catherine Guthrie	The Latest on Hormone Therapy for Women It's not often that a middle-aged former sitcom star is at the center of an important health debate. But Suzanne Somers's hormone therapy -- has put her in the limelight.
American Family Physician July 1, 2002 Vincent Morelli	Alternative Therapies for Traditional Disease States: Menopause For most women, menopause is a normal phase of life that does not require medical intervention. However, some perimenopausal women seek treatment for vasomotor symptoms, while postmenopausal women may need treatment that can reduce their risk of cardiovascular disease and osteoporosis.
American Family Physician March 15, 2004	Use of Ultra-Low-Dose Estrogen to Prevent Bone Loss Estrogen therapy recently has been shown to increase the risk of breast cancer, heart disease, stroke, and deep venous thrombosis, but it also decreases the risk of hip fracture.
The Motley Fool October 19, 2009 Brian Orelli	Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis.
American Family Physician March 15, 2004	Breast Cancer Risk Related to Type of Hormone Therapy Although several studies have demonstrated an increased risk of breast cancer in postmenopausal women taking oral hormone therapy, the risk related to each of the various forms of therapy is less clear.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.